Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06047106

Multi-parametric MRI Evaluation of Renal Graft Performance After Living Donor Donation.

The selection of kidneys from living donors is based on strict glomerular filtration rate (GFR) values, in the setting of the increasing proportion of older donors. The 2017 KDIGO recommendations consider that approving kidney donation for a donor with a GFR between 60 and 89 mL/min/1.73 m² should be individually discussed, possibly using a calculator. A GFR < 60 mL/min/1.73 m² should contraindicate donation without considering the donor's age.

GFR physiologically decreases with age, so older donors frequently have a GFR below 90 ml/min/1.73 m². However, the proportion of older donors continues to rise.

Kidney grafts from older living donors maintain better renal function than those from deceased donors, aiming to counteract the organ shortage.

Kidneys possess functional reserves, allowing an increase in GFR during stimulations and adaptation to reduced functional nephron count (as after nephrectomy). Assessing this adaptive capacity clinically is challenging. It might be dependent on vascularization and/or absence of fibrosis, but these parameters are poorly understood due to a lack of current in vivo exploration methods.

The development of functional renal MRI enables the evaluation of these parameters, allowing measurements on separate, regional, non-invasive, quantitative kidney segments coupled with morphological studies. BOLD-MRI can measure regional oxygen content, thus accessing more precise medullary data. The DWI sequence can estimate renal microstructure and study interstitial fibrosis.

Therefore, evaluating renal performance (by measuring GFR, renal perfusion, fibrosis, inflammation, and oxygen content) in donors, and studying the evolution of these parameters in recipients and donors, could optimize donor selection.

Hence, the aim of our study is to 1) investigate the evolution of renal functional parameters in the transplanted kidney up to 1 year post-transplant, and 2) study the evolution of these same parameters in the contralateral kidney of the donor.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Renal Insufficiency, Chronic Cardiovascular Diseases Chronic Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Renal Insufficiency Reperfusion Injury Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Edouard Herriot, Hospices Civils de Lyon

Lyon, 69003, France

Location status: Recruiting

Location contact

SANDRINE PU-PH LEMOINE

CONTACT

[email protected]

0687947771 ext. +33

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For recipients:

  • Patients with end-stage chronic kidney disease awaiting kidney transplant from a living donor.
  • Adult patient
  • Consent signed
  • effective contraceptive method for women
  • Patient affiliated to a social security or beneficiaries of a similar scheme

For donors:

  • Individuals eligible for living kidney donation with GFR > 60 mL/min/1.73 m².
  • Adult patient
  • Consent signed
  • effective contraceptive method for women
  • Patient affiliated to a social security or beneficiaries of a similar scheme

Exclusion criteria

For the two groups :

  • MRI contraindications (claustrophobia, pacemaker, cardioverter defibrillators implantable, mechanical heart valve non MRI-compatible)
  • Weight> 130 kg
  • Pregnant, parturient or breastfeeding
  • Persons deprived of their liberty by a judicial or administrative decision,
  • Adults subject to a legal protection measure (safeguard measure, guardianship, curators)
  • subject participating in another research including an exclusion period still in progress at inclusion

For recipients :

  • Contraindication to renal graft biopsy (ongoing or uninterrupted anticoagulant or antiplatelet treatment, thrombocytopenia <100 x 10^9/L, anemia <7 g/dL).

Treatment and study plan

multiparametric MRI

Radiation

For the living donor, multiparametric MRI will be added in the day hospital: at the pre-transplant assessment and at the 12-month post-transplant assessment.

For the recipient: multiparametric MRI will be added in the day hospital at the time of the systematic assessment at 1 month post-transplant, and will be added in the day hospital at the time of the 12-month post-transplant assessment.

kidney graft biopsy

Procedure

Biopsy of the graft itself prior to transplantation in the recipient.

blood samples

Biological

For donors who are not selected to donate their kidney, a total of 4 mL of blood will be collected at inclusion.

For donors eligible to donate, a total of 8 mL of blood will be collected (at inclusion and at 12 months post-transplant).

For recipients, a total of 32 mL of blood will be collected (pre-transplant, 1 month and 12 months post-transplant).

urine specimens

Biological

For donors who are not selected to donate their kidney, a total of 15 mL of urine will be collected at inclusion.

For donors eligible to donate, a total of 50 mL of urine will be collected (at inclusion and at 12 months post-transplant).

For recipients, a total of 65 mL of urine will be collected (pre-transplant, 1 month and 12 months post-transplant).

Primary outcomes

  1. Apparent diffusion coefficient (ADC) coefficient values measured in diffusion-weighted MRI sequence

    Time frame: Baseline before transplantation, one month and 12 months after kidney transplantation

Secondary outcomes

  1. In recipients, R2* values measured by BOLD MRI

    Time frame: Baseline before transplantation, one month and 12 months after kidney transplantation

  2. In recipients, T2 Values measured by T2 mapping MRI

    Time frame: Baseline before transplantation, one month and 12 months after kidney transplantation

  3. In recipients, T1 Values measured by T1 mapping MRI

    Time frame: Baseline before transplantation, one month and 12 months after kidney transplantation

Study contacts

Contact information is provided by the study sponsor or research team.

Marine GIRERD

CONTACT

[email protected]

04 72 11 06 20

Sandrine LEMOINE, PU-PH

CONTACT

[email protected]

04 72 11 02 44

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

DOVIMIR : Multi-parametric MRI Evaluation of Renal Graft Performance After Living Donor Donation

Acronym: DOVIMIR

Important dates

Study start
2024
Primary completion
2029
Study completion
2029
First posted
Sep 21, 2023
Registry last updated
Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.